心力衰竭中房室瓣经导管介入治疗的证据生成与实施:现状与未来方向
二尖瓣反流和三尖瓣反流是心力衰竭患者最常见的瓣膜性心脏病,具有独立预后价值。经导管介入已可用于治疗瓣膜性心脏病,其疗效和安全性已在随机对照试验中检验。然而证据仍有限且有时不确定,因试验在患者异质性、继发性房室瓣疾病动态性、心衰药物与器械作用、操作结果依赖、样本量及盲法等方面存在局限,本文综述这些问题并聚焦生成进一步证据的可能解决方案。
要点
- 二尖瓣反流和三尖瓣反流在心衰患者中常见且独立影响预后。
- 经导管介入的随机对照试验证据受患者异质性和疾病动态性等因素限制。
- 需针对试验设计局限探索解决方案以生成更可靠证据。
核心结论
- 经导管介入治疗心衰患者房室瓣疾病的证据仍有限且有时不确定,需针对试验局限改进证据生成。
研究设计与样本
- 本文为综述,聚焦心衰患者房室瓣疾病经导管介入治疗的随机对照试验证据及其局限性。
主要发现
- 二尖瓣反流和三尖瓣反流是心衰患者最常见的瓣膜性心脏病,具有独立预后价值。
- 经导管介入的疗效和安全性已在随机对照试验中检验,但证据有限且有时不确定。
- 试验解释受限因素包括患者发病机制和临床特征异质性、继发性房室瓣疾病严重度的动态性、心衰药物和器械的作用、对操作结果和操作者技能的依赖、入组患者较少及检验差异的效力、以及非盲法方案下患者报告结局的局限。
临床怎么用
- 临床应认识到经导管介入治疗心衰患者房室瓣疾病的证据局限性,结合患者具体情况审慎决策。
局限性
- 证据受患者异质性、疾病动态性、药物器械影响、操作依赖、样本量小及盲法限制等因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mitral regurgitation and tricuspid regurgitation are the most common valvular heart diseases in patients with heart failure and have independent prognostic value. Transcatheter interventions are now available for the treatment of valvular heart disease, and their efficacy and safety have been tested in randomized controlled trials. However, evidence is still limited and sometimes inconclusive because several aspects of these trials limit their interpretation or consistency. These include heterogeneity in the pathogenesis and clinical characteristics of patients, the dynamic nature of secondary atrioventricular valve disease severity, the role of heart failure medications and devices, dependency on procedural results and operators' skills, smaller number of patients enrolled and the power to detect differences in trials, and limitations to use patients' reported outcomes with unblinded study protocols. These specific aspects of trials in patients with atrioventricular valve disease are reviewed in this article with a focus on possible solutions to generate further evidence for the efficacy and safety for transcatheter treatments of atrioventricular valve disease in patients with heart failure.
引用
- Metra, Tomasoni, Adamo, et al. Evidence Generation and Implementation of Transcatheter Interventions for Atrioventricular Valvular Heart Disease in Heart Failure: Current Status and Future Directions. Circulation. 2025. PMID: 40324027. doi:10.1161/CIRCULATIONAHA.124.070411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。